NFATc1-IN-1

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

NFATc1-IN-1 (compound A04) 一种是 RANKL- 诱导的破骨细胞 (osteoclast) 形成的有效抑制剂，其 IC50 为 1.57 μM。NFATc1-IN-1 通过降低 RANKL 诱导的 NFATc1 核转位，显示抗破骨细胞 (anti-osteoclastogenic) 作用。NFATc1-IN-1 可用于破骨疾病的研究。

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research.

NFATc1-IN-1 (compound A04) (0-2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption.NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1Cell Viability Assay Cell Line:Osteoclast precursor RAW 264.7 cells Concentration:0, 0.5, 1.0, 1.5, 2.0 and 2.5 μM Incubation Time:4 days Result: Markedly reduced the number and size of red TRAP-positive multinucleated osteoclasts at concentrations of 1.5, 2.0, and 2.5 μM. Significantly inhibited formation of osteoclasts in a dose-dependent manner (at 1.5, 2.0 and 2.5 μM), while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM.Immunofluorescence Cell Line:RAW264.7 cells Concentration:1.5 or 2.5 μM Incubation Time:24 h Result:Blocked NFATc1 nuclear translocation and decreased the level of NFATc1.

——

——

Others

Other Targets

RANKL/RANK

——

——

1912422-56-0

375.11

C13H8F2INO2

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 125 mg/mL (333.24 mM; 超声助溶 )

C(NC1=C(F)C=C(I)C=C1)(=O)C2=C(O)C=CC(F)=C2

——

(-20℃)

With Ice Pack

≥ 2 years